Aveo releases final OS data on tivozanib; Ablynx reports success for PhII RA study;

 @FierceBiotech: In case you missed it: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: J&J, Pharmacyclics score 'breakthrough' coup with blockbuster hopeful ibrutinib. Article | Follow @JohnCFierce

@RyanMFierce: J&J's Alzheimer's R&D chief sticks by 'golden age' prediction after bapi bust. But where's the data? More | Follow @RyanMFierce

> Aveo ($AVEO) and Astellas reported final OS results for tivozanib's Phase III. Investigators are blaming a one-sided crossover for the fact that the OS data on the experimental drug failed to match the OS rate for Nexavar. The therapy hit the endpoint on progression-free survival. Release

> Belgium's Ablynx says it is recording positive results in a Phase II study of a new rheumatoid arthritis therapy. Release

> Peregrine ($PPHM) reports that in a Phase II study patients treated with a combination of bavituximab and gemcitabine had a 28% tumor response rate as compared to 13% in the control arm. Median OS, the primary endpoint of the trial, was 5.6 months for the bavituximab plus gemcitabine arm and 5.2 months for the control arm. Release

Pharma News

@FiercePharma: Sanofi plans to boost Lantus production in Ireland with a $59 million upgrade to Waterford site. More | Follow @FiercePharma

@EricPFierce: 2012 M&A was slow in biopharma as cos. choked down previous mega mergers. Execs may be ready to tango in 2013. Special Report | Follow @EricPFierce

@AlisonBFierce: The WHO granted PharmaJet's Stratis Needle-free Injector performance, quality and safety pre-qualification status. Release | Follow @AlisonBFierce

> U.K. gatekeepers shut out Novartis cancer treatment. News

> Discount program robs pharma to pay hospitals, report claims. Story

Medical Device News

 @FierceMedDev: Attorneys: JNJ knew of mesh problems before marketing. Article | Follow @FierceMedDev

 @MarkHFierce: Medtronic won FDA approval for its next-gen Advisa MRI-friendly pacemaker. Release | Follow @MarkHFierce

 @DamianFierce: More regulatory struggles for St. Jude as it recalls a component of its Amplatzer heart plug. Story | Follow @DamianFierce

> J&J metal hip trial stirs up renewed call for 510(k) reform. Item

> Dako inks companion diagnostics deal with Pfizer. Article

Drug Delivery News

> Alnylam joins Spanish team to deliver successful RNAi. Story

> Genelux, Sloan-Kettering test delivery of mesothelioma drug. More

> Germany grants reimbursement for Delcath's chemo delivery tech. Item

> UCLA team snuffs cancer cells with nanoshell delivery. News

> Smiths Medical wins FDA clearance for 'smart' infusion pump. Report

And Finally… Investigators at the University of Pennsylvania vet school say they found a new pathway to stimulate bone growth, and the discovery could be useful both for humans as well as animals. Release

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.